EA201691964A1 - Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии - Google Patents
Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапииInfo
- Publication number
- EA201691964A1 EA201691964A1 EA201691964A EA201691964A EA201691964A1 EA 201691964 A1 EA201691964 A1 EA 201691964A1 EA 201691964 A EA201691964 A EA 201691964A EA 201691964 A EA201691964 A EA 201691964A EA 201691964 A1 EA201691964 A1 EA 201691964A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- conjugates
- cancer
- treatment
- medicines
- delivery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
В данном документе описаны конъюгаты для доставки лекарственного средства для нацеленной терапии. В частности, в данном документе описаны конъюгаты для доставки лекарственного средства, которые включают в себя поливалентные линкеры, содержащие одну или несколько не встречающихся в природе аминокислот, которые применимы для лечения форм рака и воспалительных заболеваний.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979344P | 2014-04-14 | 2014-04-14 | |
US201462057473P | 2014-09-30 | 2014-09-30 | |
PCT/US2015/025790 WO2015160833A1 (en) | 2014-04-14 | 2015-04-14 | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201691964A1 true EA201691964A1 (ru) | 2017-04-28 |
Family
ID=54324505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691964A EA201691964A1 (ru) | 2014-04-14 | 2015-04-14 | Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии |
Country Status (10)
Country | Link |
---|---|
US (1) | US20170035894A1 (ru) |
EP (1) | EP3131587A4 (ru) |
JP (1) | JP2017516760A (ru) |
CN (1) | CN106456796A (ru) |
AU (1) | AU2015247806A1 (ru) |
CA (1) | CA2945367A1 (ru) |
EA (1) | EA201691964A1 (ru) |
IL (1) | IL248328A0 (ru) |
PH (1) | PH12016502042A1 (ru) |
WO (1) | WO2015160833A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017225982B2 (en) | 2016-03-02 | 2023-10-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
WO2018136002A1 (en) * | 2017-01-18 | 2018-07-26 | Temasek Life Sciences Laboratory Limited | Hyperstabilized liposomes increase targeting of mitotic cells |
CN111647040B (zh) * | 2020-05-11 | 2022-02-22 | 深圳市老年医学研究所 | 一种天然活性多肽Tubulysin U的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
AU2008268432B2 (en) * | 2007-06-25 | 2015-01-15 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
WO2011069116A1 (en) * | 2009-12-04 | 2011-06-09 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
MX2013005194A (es) * | 2010-11-12 | 2013-06-28 | Endocyte Inc | Metodos para el tratamiento del cancer. |
US20140080175A1 (en) * | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20140107316A1 (en) * | 2012-10-16 | 2014-04-17 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
KR20150070318A (ko) * | 2012-10-16 | 2015-06-24 | 엔도사이트, 인코포레이티드 | 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법 |
-
2015
- 2015-04-14 US US15/303,953 patent/US20170035894A1/en not_active Abandoned
- 2015-04-14 AU AU2015247806A patent/AU2015247806A1/en not_active Abandoned
- 2015-04-14 EP EP15779751.5A patent/EP3131587A4/en not_active Withdrawn
- 2015-04-14 CN CN201580030945.0A patent/CN106456796A/zh active Pending
- 2015-04-14 CA CA2945367A patent/CA2945367A1/en not_active Abandoned
- 2015-04-14 EA EA201691964A patent/EA201691964A1/ru unknown
- 2015-04-14 JP JP2016562576A patent/JP2017516760A/ja active Pending
- 2015-04-14 WO PCT/US2015/025790 patent/WO2015160833A1/en active Application Filing
-
2016
- 2016-10-13 IL IL248328A patent/IL248328A0/en unknown
- 2016-10-13 PH PH12016502042A patent/PH12016502042A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015247806A1 (en) | 2016-10-27 |
US20170035894A1 (en) | 2017-02-09 |
PH12016502042A1 (en) | 2017-01-09 |
EP3131587A4 (en) | 2017-11-01 |
CN106456796A (zh) | 2017-02-22 |
JP2017516760A (ja) | 2017-06-22 |
WO2015160833A1 (en) | 2015-10-22 |
EP3131587A1 (en) | 2017-02-22 |
IL248328A0 (en) | 2016-11-30 |
CA2945367A1 (en) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
EA201590622A1 (ru) | Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения | |
CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
EA201890006A1 (ru) | Применение экзосом для лечения болезни | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
CL2015002246A1 (es) | Conjugados de anticuerpos drogas. | |
EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
CU20170014A7 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
UY36021A (es) | Proteìnas fc multimèricas | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
EA201591925A1 (ru) | Терапевтические композиции и их применение | |
TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
CY1123366T1 (el) | Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου | |
HK1232242A1 (zh) | 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EA201890457A1 (ru) | Комбинации антитела против ox40 и модулятора tlr4 и их применение | |
MA50764A (fr) | Linkers peptidiques et conjugués de cryptophycine, utiles en thérapie, et leur préparation | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
MX2017007054A (es) | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |